In collaboration with UC Irvine and the California Institute for Regenerative Medicine, jCyte is sponsoring a Phase 2b clinical trial to investigate our developmental stem cell therapy to treat retinitis pigmentosa (RP). This potentially groundbreaking approach is designed to preserve and potentially improve vision for patients with RP.
To assess the treatment’s safety and efficacy, jCyte has contracted with The Gavin Herbert Eye Institute at the University of California, Irvine and Retinal-Vitreous Associates Medical Group to conduct the trial. The UC San Francisco Department of Ophthalmology will also participate.
These clinical sites are now recruiting patients for the Phase 2b trial. Participants will receive a single, minimally-invasive intravitreal (inside the eye) injection of human retinal progenitor cells (jCell) in their worst-seeing eye. This outpatient therapy does not require surgery.
The trial’s primary objective is to assess whether jCell can improve eyesight. The study will assess participants’ visual function for 12 months following treatment, measuring visual acuity, color recognition and contrast sensitivity. Participants will also be asked to navigate a mobility course at different light levels. The study will also investigate jCell’s safety and tolerability.
In addition to the initial treatment, participants will be required to make several follow-up visits to various clinical sites. Patients will not be charged to participate in the trial.
You may be eligible for this study if you:
- Have been diagnosed with retinitis pigmentosa
- Are 18 or older
- Visual acuity no better than 20/40 and no worse than 20/1000 in both eyes
If you are interested in participating, please contact jCyte to request more information.
- Email: email@example.com
- Phone: 714-509-2151